FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206500116> ?p ?o ?g. }

• W4206500116 abstract "<p>Asthma is a common, heterogeneous condition where current treatment options are limited to a ‘one size fits all’ approach. Biological therapies targeting specific components of the Type 2 inflammatory pathway are emerging as potential alternatives for those who are inadequately controlled on current treatment options. Biomarkers, such as serum periostin, can be used in clinical settings to identify potential responders to these treatments. The aim of this research was to investigate the epidemiology of periostin and its ability to predict important clinical outcomes in asthma. Six studies were conducted: two cohort studies observing the change to periostin after bone and dental injury in non-asthmatic adults; a cohort study investigating reference ranges of periostin in Chinese adults with and without asthma; two longitudinal studies measuring the change in periostin in asthmatic adults with stable and unstable disease; and a longitudinal cohort study investigating the association between periostin and risk of exacerbation. There was a biphasic response of serum periostin after bone injury. This was particularly marked after joint replacement surgery where periostin fell within 48 hours by a ratio of geometric means 0.80 (95% CI 0.75 to 0.86) before rising to a maximum level at eight weeks with a ratio of geometric means 1.89 (95% CI 1.77 to 2.02). There was no significant change to periostin after simple or surgical tooth extractions with a maximal ratio of geometric means of 1.02 (95% CI 0.95 to 1.10). Serum periostin was higher in Chinese non-asthmatic adults versus Caucasian non- asthmatic adults, mean periostin 57 ng/ml and 49.7 ng/ml respectively, difference (95% CI) 8.2 (5.8 to 10.6) ng/ml. Serum periostin remained stable in adults with well- controlled asthma with an intra-class coefficient for variation of 0.93. In unstable asthma, there was a decrease in serum periostin one week after the start of a severe exacerbation and treatment with systemic corticosteroids, with a ratio of geometric means 0.86 (95% CI 0.82 to 0.92) before stabilising four weeks later. Finally, adults with mild to moderate asthma with low baseline levels of periostin were more likely to have a severe asthma exacerbation with a hazard ratio (95% CI) 0.62 (0.35 to 1.09) per 0.693 ng/ml increase of log periostin. In conclusion, serum periostin showed significant biphasic variation in response to bone injury, the magnitude and duration of which was proportional to bone size. Whilst this pattern was not replicated in adults undergoing dental surgery, it suggests that serum periostin can be affected by non-asthma related conditions. Periostin demonstrated higher mean values in Chinese adults than in Caucasian adults, indicating ethnicity-specific reference ranges may be required if it were to become a clinical biomarker. Intra-participant variability of serum periostin was low in a homogenous group of well controlled, moderate to severe asthmatic adults, but there was wide variability between individuals in this group suggesting that factors other than asthma are likely to affect serum periostin levels. Serum periostin was suppressed during and after treatment for a severe exacerbation for up to four weeks. This is likely due to the exacerbation and/or its treatment, suggesting the interpretation of periostin as a biomarker for response to biological therapies should not occur within four weeks of a severe exacerbation. The reported positive association between periostin and risk of severe exacerbation in populations with severe eosinophilic asthma does not extend to a general population of mild to moderate asthmatics, in which an inverse associated was observed. Serum periostin may be useful in predicting treatment responsiveness of patients to monoclonal antibody therapy directed against IL-4Rα, IL-13 and IgE. However, it may be difficult to use as a biomarker clinically, as numerous non-asthma related factors, such as bone injury and ethnicity, have been shown to significantly affect serum levels, making interpretation difficult.</p>" @default.
• W4206500116 created "2022-01-25" @default.
• W4206500116 creator A5059242742 @default.
• W4206500116 creator A9999999999 @default.
• W4206500116 date "2021-12-07" @default.
• W4206500116 modified "2023-10-11" @default.
• W4206500116 title "Periostin - A biomarker in adults with asthma" @default.
• W4206500116 doi "https://doi.org/10.26686/wgtn.17136371" @default.
• W4206500116 hasPublicationYear "2021" @default.
• W4206500116 type Work @default.
• W4206500116 citedByCount "0" @default.
• W4206500116 crossrefType "dissertation" @default.
• W4206500116 hasAuthorship W4206500116A5059242742 @default.
• W4206500116 hasAuthorship W4206500116A9999999999 @default.
• W4206500116 hasBestOaLocation W42065001161 @default.
• W4206500116 hasConcept C107130276 @default.
• W4206500116 hasConcept C126322002 @default.
• W4206500116 hasConcept C185592680 @default.
• W4206500116 hasConcept C189165786 @default.
• W4206500116 hasConcept C201903717 @default.
• W4206500116 hasConcept C2776042228 @default.
• W4206500116 hasConcept C2777014857 @default.
• W4206500116 hasConcept C2777699602 @default.
• W4206500116 hasConcept C2781197716 @default.
• W4206500116 hasConcept C55493867 @default.
• W4206500116 hasConcept C71924100 @default.
• W4206500116 hasConcept C72563966 @default.
• W4206500116 hasConcept C86803240 @default.
• W4206500116 hasConcept C95444343 @default.
• W4206500116 hasConceptScore W4206500116C107130276 @default.
• W4206500116 hasConceptScore W4206500116C126322002 @default.
• W4206500116 hasConceptScore W4206500116C185592680 @default.
• W4206500116 hasConceptScore W4206500116C189165786 @default.
• W4206500116 hasConceptScore W4206500116C201903717 @default.
• W4206500116 hasConceptScore W4206500116C2776042228 @default.
• W4206500116 hasConceptScore W4206500116C2777014857 @default.
• W4206500116 hasConceptScore W4206500116C2777699602 @default.
• W4206500116 hasConceptScore W4206500116C2781197716 @default.
• W4206500116 hasConceptScore W4206500116C55493867 @default.
• W4206500116 hasConceptScore W4206500116C71924100 @default.
• W4206500116 hasConceptScore W4206500116C72563966 @default.
• W4206500116 hasConceptScore W4206500116C86803240 @default.
• W4206500116 hasConceptScore W4206500116C95444343 @default.
• W4206500116 hasLocation W42065001161 @default.
• W4206500116 hasLocation W42065001162 @default.
• W4206500116 hasOpenAccess W4206500116 @default.
• W4206500116 hasPrimaryLocation W42065001161 @default.
• W4206500116 hasRelatedWork W1908758969 @default.
• W4206500116 hasRelatedWork W2229663281 @default.
• W4206500116 hasRelatedWork W2547126722 @default.
• W4206500116 hasRelatedWork W2550950923 @default.
• W4206500116 hasRelatedWork W2551932183 @default.
• W4206500116 hasRelatedWork W2790646679 @default.
• W4206500116 hasRelatedWork W2809702058 @default.
• W4206500116 hasRelatedWork W2999893877 @default.
• W4206500116 hasRelatedWork W4254896204 @default.
• W4206500116 hasRelatedWork W3153107561 @default.
• W4206500116 isParatext "false" @default.
• W4206500116 isRetracted "false" @default.
• W4206500116 workType "dissertation" @default.